main content start
¿Le gustó este contenido?
Content
Oncology 1m 36s

Enhancing Global Access to Cancer Medicines

Downloadable slides curated by experts

Please watch the video to access Medslides

Publicado20 Jul 2022
Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease. For those of us who practice in low resource settings these advances bring hope for future but access to cancer treatment remains challenge that needs to be addressed. It is imperative for stakeholders to increase access to cancer medicines around the world. We need to use policy frameworks, increase the usage of generics & Biosimilar for off patent drugs & explore innovative funding mechanisms for those medications still under patient protection.
biosimilars access generics

Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.

Ventajas de registrarse en MedEnrich
Contenido en línea en varios formatos
Contenido personalizado
Acceso ilimitado a todas las funciones
Hi, can I help?
Chat de ayudaX
Equipo de soporte
¡Hola! ¿Cómo puedo ayudarlo/a hoy?
Por favor seleccione alguna de las siguientes opciones.

Buscar información

Problemas con el inicio de sesión o registro

Compartir un comentario